f APOBEC3F and APOBEC3G cytidine deaminases potently inhibit human immunodeficiency virus type 1 (HIV-1) replication by enzymatically inserting G-to-A mutations in viral DNA and/or impairing viral reverse transcription independently of their deaminase activity. Through experimental and mathematical investigation, here we quantitatively demonstrate that 99.3% of the antiviral effect of APOBEC3G is dependent on its deaminase activity, whereas 30.2% of the antiviral effect of APOBEC3F is attributed to deaminase-independent ability. This is the first report quantitatively elucidating how APOBEC3F and APOBEC3G differ in their anti-HIV-1 modes.
Human immunodeficiency virus type 1 (HIV-1), the causative agent of AIDS, hijacks lines of cellular proteins for its replication (reviewed in reference 1). On the other hand, accumulating evidence has revealed that human cells intrinsically possess anti-HIV-1 proteins (reviewed in reference 2). Human apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3) proteins are cellular cytidine deaminases, and certain APOBEC3 proteins, particularly APOBEC3F (3, 4) and APOBEC3G (5), are the intrinsic restriction factors against HIV-1. APOBEC3F and APOBEC3G are incorporated into assembling HIV-1 particles and brought into the newly infected cells. During reverse transcription (RT) in the infected cells, these APOBEC3 proteins enzymatically convert C in the viral minus-strand DNA to U, resulting in G-to-A mutation in the nascent plus-strand DNA. These mutations can become nonsynonymous or even lethal, which severely debilitates subsequent viral replication.To antagonize these APOBEC3F-and APOBEC3G-mediated antiviral effect, viral infectivity factor (Vif), an accessory protein of HIV-1, degrades APOBEC3F and APOBEC3G through a ubiquitin/proteasome-dependent pathway (reviewed in references 6 and 7). Previous studies have directly demonstrated that Vif is a prerequisite for HIV-1 replication in vitro (e.g., human primary CD4 ϩ T lymphocytes and macrophages) (8, 9) and in vivo (e.g., humanized mouse models) (10, 11). Moreover, G-to-A mutations have been clearly observed in the proviral DNA of HIV-1-infected patients, although the frequencies of G-to-A mutations seem to vary among individuals (12-23).It has been reported that the incorporated APOBEC3F and APOBEC3G potently impair the HIV-1 RT process even prior to the insertion of G-to-A mutations (24-26). Moreover, this inhibition is independent of these APOBEC3s' deaminase activity (26). These findings indicate that APOBEC3F and APOBEC3G potently inhibit HIV-1 replication through at least two distinct modes: (i) deaminase activity-dependent G-to-A mutations of viral DNA and (ii) impairment of viral RT independent of deaminase activity (Fig. 1). However, how much of the inhibition of HIV-1 replication by APOBEC3 proteins is attributed to each of these two modes has not been quantitatively revealed.In order to quantitatively determine the relative extent of deaminase activity-dependent and -independent antiviral activity of ...